Pfizer Corporation

Esther C Lee

Meihua Mike Tu

Kevin James Filipski

Angel Guzman-Perez

Jeffrey Allen Pfefferkorn

Mary Theresa Didiuk

Benjamin Dawson Stevens

Kimberly O Cameron

Samit Kumar Bhattacharya

Matthew Scott Dowling

Benjamin C Stevens

Aaron Smith

Dilinie Fernando

Daniel W Kung

David Christopher Ebner

The present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R, R, R, A, A, A, B, B, Band Bare as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.

Quinolinyl glucagon receptor modulators

The present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R, R, R, A, A, A, B, B, Band Bare as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon. 

The present invention relates to indole and indazole compounds of Formula (I) that activate 5' adenosine monophosphate-activated protein kinase (AMPK). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating or preventing diseases, conditions, or disorders ameliorated by activation of AMPK.

Indole and indazole compounds that activate AMPK

Growing community of inventors

Brookline, MA, United States of America

Esther C Lee